Zydus Lifesciences has received approval from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg dosages. These tablets, a synthetic form of the thyroid hormone T3, are primarily used for treating hypothyroidism. The annual sales for Liothyronine tablets in Canada were CAD 10.9 million as of June 2025. This approval allows Zydus to expand its presence in the Canadian pharmaceutical market.
Canadian Market Expansion
Zydus Lifesciences Limited has secured Notice of Compliance (NOC) from Health Canada for its generic version of Liothyronine tablets, available in 5 mcg and 25 mcg strengths. The approval, announced on October 6, 2025, signifies a key regulatory milestone that helps expand Zydus’s reach.
Liothyronine Tablets Overview
Liothyronine tablets are a synthetic form of the thyroid hormone T3 (triiodothyronine). The medication is primarily prescribed for treating hypothyroidism. With this approval, Zydus aims to address a crucial need in the Canadian market.
Market Performance and Manufacturing
Zydus will manufacture these tablets at its plant in Ahmedabad SEZ. According to IQVIA data, the annual sales of Liothyronine tablets in Canada amounted to CAD 10.9 million as of June 2025, indicating a considerable market opportunity for Zydus following this regulatory approval.
Source: BSE
